Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Details)

v3.21.2
Segment Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
USD ($)
Segment Reporting [Abstract]                
Number of operating segments | segment             2  
Segment Reporting Information [Line Items]                
Total revenue $ 121,340     $ 125,444     $ 358,597 $ 318,451
Total cost of revenue 74,101     71,379     216,794 190,011
Total gross profit 47,239     54,065     141,803 128,440
General and administrative 63,839     36,128     158,953 107,085
Research and development 7,409     1,964     13,360 6,129
Sales and marketing 15,704     11,304     46,677 34,757
Total operating expenses 86,952     49,396     218,990 147,971
Loss (income) from operations (39,713)     4,669     (77,187) (19,531)
Interest expense, net 1,296     2,458     3,375 4,825
Other income, net (89)     (11)     (431) (7,639)
Gain on investment in and loan receivable from non-consolidated affiliate, net (17,750)     0     (109,260) 0
Loss on extinguishment of debt 0     0     0 1,400
Loss on termination of cash flow hedge 0     0     0 3,506
(Loss) income before taxes (23,170)     2,222     29,129 (21,623)
Income tax benefit (2,822)     (335)     (4,283) (10,378)
Net (loss) income (20,348) $ 75,873 $ (22,114) 2,557 $ (6,824) $ (6,978) 33,412 (11,245)
Clinical Services                
Segment Reporting Information [Line Items]                
Total revenue 102,227     108,733     300,119 275,599
Total cost of revenue 59,560     60,607     178,358 158,287
Total gross profit 42,667     48,126     121,761 117,312
Amortization of acquired intangible assets 4,300           5,000  
Clinical Services | COVID-19 PCR Testing                
Segment Reporting Information [Line Items]                
Write off of COVID-19 PCR testing inventory             5,300  
Pharma Services                
Segment Reporting Information [Line Items]                
Total revenue 19,113     16,711     58,478 42,852
Total cost of revenue 14,541     10,772     38,436 31,724
Total gross profit 4,572     $ 5,939     20,042 $ 11,128
Amortization of acquired intangible assets $ 500           $ 500